nach oben

Current Rheumatology Reports

Erschienen in:

26.04.2021 | COVID-19 | Infections and Arthritis (K Winthrop, Section Editor) Zur Zeit gratis

COVID-19 and Disease-Modifying Anti-rheumatic Drugs

verfasst von: Kristin M. D’Silva, Zachary S. Wallace

Erschienen in: Current Rheumatology Reports | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Patients on disease-modifying anti-rheumatic drugs (DMARDs) remain concerned about potential risks of severe COVID-19 outcomes. Meanwhile, several DMARDs have been proposed as COVID-19 therapies.

Recent Findings

In patients with autoimmune diseases, baseline glucocorticoid use is associated with severe COVID-19. While classes of DMARDs (e.g., conventional synthetic, targeted synthetic, and biologic) do not appear to be associated with higher risk, specific medications such as rituximab and sulfasalazine may be associated. Randomized clinical trials (RCTs) show that glucocorticoids reduce mortality in severe COVID-19. RCTs suggest other agents, such as baricitinib, may improve COVID-19 outcomes in certain populations.

Summary

Baseline glucocorticoid use raises the risk of severe COVID-19 in patients with autoimmune diseases, but glucocorticoids are an effective treatment for those with severe COVID-19. Further research is needed to inform DMARD management in autoimmune disease patients during the pandemic and the role of DMARDs in COVID-19 treatment.

Coronavirus disease 2019 dashboard: World Health Organization; [2-3-21]. Available from: https://covid19.who.int/.

Michaud K, Wipfler K, Shaw Y, Simon TA, Cornish A, England BR, et al. Experiences of patients with rheumatic diseases in the US during early days of the COVID-19 pandemic. ACR Open Rheumatol. 2020;2(6):335–43.PubMedPubMedCentralCrossRef

Sattui SE, Liew JW, Graef ER, Coler-Reilly A, Berenbaum F, Duarte-García A, et al. Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. Expert Rev Clin Immunol. 2020;16(7):659–66.PubMedPubMedCentralCrossRef

• Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of tocilizumab in patients hospitalized with COVID-19. N Engl J Med. 2020;383:2333–44 This early RCT of tocilizumab vs. placebo in hospitalized COVID-19 showed no effect of tocilizumab on COVID-19 outcomes.PubMedCrossRef

•• Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in patients hospitalized with COVID-19 pneumonia. N Engl J Med. 2021;384:20–30 This RCT of tocilizumab vs. placebo in patients hospitalized with COVID-19 showed lower risk of intubation or death at 28 days in the tocilizumab-treated arm.PubMedCrossRef

•• Gianfrancesco MA, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al. Characteristics associated with hospitalization for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79:859–66 In this study from the Global Rheumatology Alliance physician-reported registry, prednisone doses above 10 mg daily were associated with higher odds of hospitalization in rheumatic disease patients with COVID-19, while biologic/targeted synthetic DMARDs and TNF inhibitors were associated with lower odds of hospitalization.PubMedCrossRef

•• Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;Advance online publication. In this follow-up study from the Global Rheumatology Alliance physician-reported reigstry, rheumatic disease patients on rituximab, sulfasalazine, or certain immunosuppressants (including azathioprine, cyclophosphamide, cyclosporine, mycophenolate, or tacrolimus) had higher odds of death than comparators on methotrexate monotherapy.

• Brenner EJ, Ungaro RC, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel disease: results from an international registry. Gastroenterology. 2020;159(2):481–91 In a physician-reported registry of inflammatory bowel disease patients with COVID-19, prednisone and sulfasalazine were associated with higher odds of severe COVID-19 compared to non-users of these medications.PubMedPubMedCentralCrossRef

• Ungaro RC, Brenner EJ, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut. 2020;Advance online publication. In a follow-up study of inflammatory bowel disease patients with COVID-19 in a physician-reported registry, thiopurines and mesalamine/sulfasalazine were associated with higher odds of severe COVID-19 compared to TNF inhibitor monotherapy.

10.

•• Mahil SK, Dand N, Mason KJ, ZZN Y, Tsakok T, Meynell F, et al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study. J Allergy Clin Immunol. 2020;147(1):60–71 In a physician-reported registry of psoriasis patients with COVID-19, patients on non-biologics had higher odds of hospitalization compared to patients on biologics. Importantly, accompanying patient-reported data showed greater adherence to social distancing measures in patients on biologics.PubMedPubMedCentralCrossRef

11.

•• Horby PW, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with COVID-19: preliminary report. N Engl J Med. 2020;Advance online publication. This large RCT of dexamethasone vs. usual care was the first study to report that glucocorticoids lowered the risk of mortality in patients hospitalized with COVID-19.

12.

Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19. JAMA. 2020;324(13):1317–29.PubMedPubMedCentralCrossRef

13.

•• Self WH, Semler MW, Leither LM, Casey JD, Angus DC, Brower RG, et al. Effect of Hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19. JAMA. 2020;324(21):2165–76 This RCT of hydroxychloroquine vs. placebo in patients hospitalized with COVID-19 showed that hydroxychloroquine did not improve clinical status or mortality.PubMedCrossRef

14.

•• Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate COVID-19. N Engl J Med. 2020;383(21):2041–52 This RCT of hydroxychloroquine vs. hydroxychloroquine and azithromycin vs. usual care in patients hospitalized with COVID-19 showed no improvement in clinical status with either hydroxychloroquine regimen. Additionally, both hydroxychloroquine regimens were associated with QT prolongation and elevated liver enzymes.PubMedCrossRef

15.

•• RECOVERY Collaborative Group. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020;383(21):2030–40 This RCT of hydroxychloroquine vs. usual care in patients hospitalized with COVID-19 showed that patients treated with hydroxychloroquine were more likely to experience intubation or death compared to those receiving usual care.CrossRef

16.

Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. JAMA Intern Med. 2021;181(1):24–31.PubMedCrossRef

17.

Rosas I, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in hospitalized patients with COVID-19 pneumonia. medRxiv. 2020;Advance online publication.

18.

Hermine O, Mariette X, Tharaux P-L, Resche-Rigon M, Porcher R, Ravaud P. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia. JAMA Intern Med. 2021;181(1):32–40.PubMedCrossRef

19.

•• Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report. medRxiv. 2021;Advance online publication. This RCT of tocilizumab or sarilumab vs. usual care in patients with COVID-19 requiring intensive care showed a greater number of organ support-free days and greater survival in the arm receiving IL-6 receptor inhibitor therapy.

20.

•• Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med. 2020;Advance online publication. This RCT of baricitinib vs. placebo on background remdesivir therapy in hospitalized COVID-19 showed shorter time to recovery in the baricitinib-treated arm.

21.

• Bureau S, Dougados M, Tibi A, Azoulay E, Cadranel J, Emmerich J, et al. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med. 2021;Advance online publication. This RCT of anakinra vs. usual care in patients hospitalized with COVID-19 showed no effect on clinical status or a composite outcome of intubation or death.

22.

• Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos GD, Giotaki SG, Gargalianos P, et al. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019. JAMA Netw Open. 2020;3(6):1–14 This RCT of colchicine vs. usual care in patients hospitalized with COVID-19 showed longer time to deterioration in the colchicine-treated arm.CrossRef

23.

• Lopes MIF, Bonjorno LP, Giannini MC, Amaral NB, Benatti MN, Rezek UC, et al. Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial. medRxiv. 2020;Advance online publication. This interim analysis of a RCT of colchicine vs. placebo showed reduced days of oxygen needed and days of hospitalization in the colchicine-treated arm.

24.

• Tardif J-C, Bouabdallaoui N, L’Allier PL, Gaudet D, Shah B, Pillinger MH, et al. Efficacy of colchicine in non-hospitalized patients with COVID-19. medRxiv. 2021;Advance online publication. This RCT of colchicine vs. placebo in non-hospitalized COVID-19 showed a trend towards reduced risk of hospitalization or death in the colchicine-treated arm, although the trial was stopped early due to logistical reasons, limiting interpretability.

25.

Haberman R, Axelrad J, Chen A, Castillo R, Yan D, Izmirly P, et al. COVID-19 in immune-mediated inflammatory diseases - case series from New York. N Engl J Med. 2020;383:85–8.PubMedCrossRef

26.

Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis. 2020;79(5):667–8.PubMedPubMedCentralCrossRef

27.

Tomelleri A, Sartorelli S, Campochiaro C, Baldissera EM, Dagna L. Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey. Ann Rheum Dis. 2020;79(9):1252–3.PubMedPubMedCentralCrossRef

28.

Favalli EG, Ingegnoli F, Cimaz R, Caporali R. What is the true incidence of COVID-19 in patients with rheumatic diseases? Ann Rheum Dis. 2021;80(2):1.CrossRef

29.

Emmi G, Battiol A, Mattioli I, Silvestri E, Di Scala G, Urban ML, et al. SARS-CoV-2 infection among patients with systemic autoimmune diseases. Autoimmun Rev. 2020;19:1–5.CrossRef

30.

Michelena X, Borrell H, Lopez-Corbeto M, Lopez-Lasanta M, Moreno E, Pascual-Pastor M, et al. Incidence of COVID-19 in a cohort of adult and pediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum. 2020;50:564–70.PubMedPubMedCentralCrossRef

31.

Conticini E, Bargagli E, Bardelli M, Rana GD, Baldi C, Cameli P, et al. COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs. Ann Rheum Dis. 2021;80(0):1–2.

32.

Williamson E, Walker AJ, Bhaskaran KJ, Bacon S, Bates C, Morton CE, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. Nature. 2020;584:430–6.PubMedCrossRef

33.

Ye C, Cai S, Shen G, Guan H, Zhou L, Hu Y, et al. Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China. Ann Rheum Dis. 2020;79:1007–13.PubMedPubMedCentralCrossRef

34.

D’Silva KM, Serling-Boyd N, Wallwork R, Hsu TYT, Fu X, Gravallese EM, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a United States “hot spot”. Ann Rheum Dis. 2020;79:1156–62.PubMedPubMedCentralCrossRef

35.

Kaneko N, Kuo H-H, Boucau J, Farmer JR, Allard-Chamard H, Mahajan VS, et al. Loss of Bcl-6-expressing T follicular helper cells and germinal centers in COVID-19. Cell. 2020;183:1–15.CrossRef

36.

Karki R, Sharma BR, Tuladhar S, Williams EP, Zalduondo L, Samir P, et al. Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell. 2021;184(1):149–68.PubMedCrossRef

37.

Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, et al. American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the covid-19 pandemic: version 2. Arthritis Rheumatol. 2020;72(9):e1–e12.PubMedCrossRef

38.

Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical–therapeutic staging proposal. J Heart Lung Transplant. 2020;39(5):405–7.PubMedPubMedCentralCrossRef

39.

Lu C, Li S, Liu Y. Role of immunosuppressive therapy in rheumatic diseases concurrent with covid-19. Ann Rheum Dis. 2020;79:737–9.PubMedCrossRef

40.

Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19. JAMA. 2020;324(13):1330–41.PubMedCrossRef

41.

Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden LR, Cheng VC, et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-192021 [2-4-21]. Available from: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. Accessed 4 Feb 2021.

42.

Putman M, Chock YPE, Tam H, Kim AHJ, Sattui SE, Berenbaum F, et al. Antirheumatic disease therapies for the treatment of COVID-19: a systematic review and meta-analysis. Arthritis Rheum. 2020; Advance online publication.

43.

Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19. N Engl J Med. 2020;383(6):517–25.PubMedCrossRef

44.

Abella BS, Jolkovsky EL, Biney BT, Uspal JE, Hyman MC, Frank I, et al. Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers. JAMA Intern Med. 2020; Advance online publication.

45.

Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:1–11.

46.

Mitjà O, Corbacho-Monné M, Ubals M, Tebe C, Peñafiel J, Tobias A, et al. Hydroxychloroquine for early treatment of adults with mild COVID-19: a randomized-controlled trial. Clin Infect Dis. 2020; Advance online publication.

47.

Mitjà O, Corbacho M, G-Beiras C, Tebé C, Tobias A, Ballana E, et al. Hydroxychloroquine alone or in combination with cobicistat-boosted darunavir for treatment of mild COVID-19: A Cluster-Randomized Clinical Trial. SSRN Electron J. 2020; Advance online publication.

48.

Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, et al. Hydroxychloroquine in nonhospitalized adults with early COVID-19. Ann Intern Med. 2020;173(8):623–31.PubMedCrossRef

49.

WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19 — Interim WHO Solidarity Trial Results. N Engl J Med. 2020; Advance Online Publication.

50.

Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. 2020;92(7):814–8.PubMedCrossRef

51.

Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, et al. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med. 2021;181(1):41–51.PubMedCrossRef

52.

Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30–1.PubMedPubMedCentralCrossRef

53.

Amigues I, Pearlman AH, Patel A, Reid P, Robinson PC, Sinha R, et al. Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation. Expert Rev Clin Immunol. 2020;16(12):1185–204.PubMedCrossRef

54.

Zhong J, Tang J, Ye C, Dong L. The immunology of COVID-19: is immune modulation an option for treatment? Lancet Rheumatol. 2020;2(7):e428–e36.PubMedPubMedCentralCrossRef

55.

Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome. Crit Care Med. 2016;44(2):275–81.PubMedPubMedCentralCrossRef

56.

Ong EZ, Chan YFZ, Leong WY, Lee NMY, Kalimuddin S, Haja Mohideen SM, et al. A dynamic immune response shapes COVID-19 progression. Cell Host Microbe. 2020;27(6):879–82.PubMedPubMedCentralCrossRef

57.

Navarro-Millán I, Sattui SE, Lakhanpal A, Zisa D, Siegel CH, Crow MK. Use of anakinra to prevent mechanical ventilation in severe COVID-19: a case series. Arthritis Rheum. 2020;72(12):1990–7.CrossRef

58.

Balkhair A, Al-Zakwani I, Al Busaidi M, Al-Khirbash A, Al Mubaihsi S, Bataher H, et al. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: results of a prospective, open-label, interventional study. Int J Infect Dis. 2021;103:288–96.PubMedCrossRef

59.

Kooistra EJ, Waalders NJB, Grondman I, Janssen NAF, De Nooijer AH, Netea MG, et al. Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study. Crit Care. 2020;24(1):688–99.PubMedPubMedCentralCrossRef

60.

Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020;2(7):393–400.CrossRef

61.

Robinson PC, Liew DFL, Liew JW, Monaco C, Richards D, Shivakumar S, et al. The potential for repurposing anti-TNF as a therapy for the treatment of COVID-19. Med. 2020;1(1):90–102.PubMedCrossRef

62.

Reyes AZ, Hu KA, Teperman J, Wampler Muskardin TL, Tardif J-C, Shah B, et al. Anti-inflammatory therapy for COVID-19 infection: the case for colchicine. Ann Rheum Dis. 2020; Advance online publication.

63.

Scarsi M, Piantoni S, Colombo E, Airó P, Richini D, Miclini M, et al. Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. Ann Rheum Dis. 2020; Advance online publication.

Titel: COVID-19 and Disease-Modifying Anti-rheumatic Drugs
verfasst von: Kristin M. D’Silva
Zachary S. Wallace
Publikationsdatum: 26.04.2021
Verlag: Springer US
Schlagwort: COVID-19
Erschienen in: Current Rheumatology Reports / Ausgabe 5/2021
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-021-00998-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2021

Involvement of Macrophages and Spinal Microglia in Osteoarthritis Pain

Recent Updates in the Immunopathology of Type 3 Immunity-Mediated Enthesitis

Clinical Characteristics of Myositis Associated with Graft-Versus-Host Disease